000			nab a22 7a 4500
999			_c16367 _d16367
003			PC16367
005			20210505124246.0
008			210426b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_92424 _aFresno Valencia, María Rosa del _ePediatría
100			_92821 _aPeralta, Julio E _ePediatría
100			_9851 _aGranados Ruiz, Miguel Ángel _ePediatría
100			_92109 _aEnríquez Merayo, Eugenia _eReumatología Pediátrica
100			_92107 _aDomínguez Pinilla, Nerea _ePediatría
100			_91416 _aInocencio Arocena, Jaime de _ePediatría
245	0	0	_aIntravenous immunoglobulin therapy for refractory recurrent pericarditis. _h[caso clínico]
260			_aPediatrics, _c2014
300			_ae1441-6.
500			_aFormato Vancouver: Del Fresno MR, Peralta JE, Granados MÁ, Enríquez E, Domínguez-Pinilla N, de Inocencio J. Intravenous immunoglobulin therapy for refractory recurrent pericarditis. Pediatrics. 2014 Nov;134(5):e1441-6.
501			_aPMID: 25287461
504			_aContiene 28 referencias
520			_aRecurrent pericarditis is a troublesome complication of idiopathic acute pericarditis and occurs more frequently in pediatric patients after cardiac surgery (postpericardiotomy syndrome). Conventional treatment with nonsteroidal antiinflammatory drugs, corticosteroids, and colchicine is not always effective or may cause serious adverse effects. There is no consensus, however, on how to proceed in those patients whose disease is refractory to conventional therapy. In such cases, human intravenous immunoglobulin, immunosuppressive drugs, and biological agents have been used. In this report we describe 2 patients with refractory recurrent pericarditis after cardiac surgery who were successfully treated with 3 and 5 monthly high-dose (2 g/kg) intravenous immunoglobulin until resolution of the effusion. Our experience supports the effectiveness and safety of this therapy.
710			_9446 _aServicio de Pediatría-Neonatología
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc16367.pdf _ySolicitar documento
942			_2ddc _cCAS _n0